Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 249 Rectal Neoplasms 154 Pancreatic Neoplasms 125 Stomach Neoplasms 105 Colonic Neoplasms 104 Esophageal Neoplasms 90 Neoplasm Metastasis 69 Breast Neoplasms 61 Squamous Cell Carcinoma of Head and Neck 47 Carcinoma, Hepatocellular 42 Adenocarcinoma Of Esophagus 41 Head and Neck Neoplasms 39 Esophageal Squamous Cell Carcinoma 38 Neoplasms 37 Nasopharyngeal Carcinoma 30 Adenocarcinoma 24 Cholangiocarcinoma 20 Keratosis, Actinic 17 Carcinoma, Squamous Cell 16 Biliary Tract Neoplasms 16 Liver Neoplasms 15 Gastrointestinal Neoplasms 15 Anus Neoplasms 14 Gallbladder Neoplasms 11 Bile Duct Neoplasms 11 Peritoneal Neoplasms 10 Laryngeal Neoplasms 9 Recurrence 8 Nasopharyngeal Neoplasms 7 Colorectal Cancer Metastatic 7

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Fluorouracil × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡